Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Leonard N Chen

Showing results (11-20 of 31) with videos related to

Pageof 4
Sort By:
Scientific Reports|February 17, 2022
mRNA vaccine-induced antibodies more effective than natural immunity in neutralizing SARS-CoV-2 and its high affinity variantsYunkai Yu, Dominic Esposito, Zhigang Kang, et al.
Acta Oncologica (Stockholm, Sweden)|May 15, 2015
Late urinary toxicity modeling after stereotactic body radiotherapy (SBRT) in the definitive treatment of localized prostate cancerThomas P Kole, Michael Tong, Binbin Wu, et al.
Frontiers in Oncology|August 5, 2016
Proctitis 1 Week after Stereotactic Body Radiation Therapy for Prostate Cancer: Implications for Clinical Trial DesignIma Paydar, Robyn A Cyr, Thomas M Yung, et al.
Frontiers in Oncology|July 21, 2015
Dysuria Following Stereotactic Body Radiation Therapy for Prostate CancerEinsley-Marie Janowski, Thomas P Kole, Leonard N Chen, et al.
Frontiers in Oncology|December 19, 2013
Rationale for stereotactic body radiation therapy in treating patients with oligometastatic hormone-naïve prostate cancerOnita Bhattasali, Leonard N Chen, Michael Tong, et al.
Radiation Oncology (London, England)|April 19, 2015
Hematuria following stereotactic body radiation therapy (SBRT) for clinically localized prostate cancerMarie K Gurka, Leonard N Chen, Aditi Bhagat, et al.
Frontiers in Oncology|November 7, 2014
Improved irritative voiding symptoms 3 years after stereotactic body radiation therapy for prostate cancerZaker Rana, Robyn A Cyr, Leonard N Chen, et al.
Frontiers in Oncology|June 1, 2016
Acute Urinary Morbidity Following Stereotactic Body Radiation Therapy for Prostate Cancer with Prophylactic Alpha-Adrenergic Antagonist and Urethral Dose ReductionMichael C Repka, Shan Guleria, Robyn A Cyr, et al.
The Journal of Infectious Diseases|June 5, 2021
Naturally Acquired SARS-CoV-2 Immunity Persists for Up to 11 Months Following InfectionValeria De Giorgi, Kamille A West, Amanda N Henning, et al.
Radiation Oncology (London, England)|February 12, 2014
Patient-reported outcomes following stereotactic body radiation therapy for clinically localized prostate cancerOnita Bhattasali, Leonard N Chen, Jennifer Woo, et al.
Pageof 4

Showing results (11-20 of 31) with videos related to

Sort By:
Pageof 4
Scientific Reports|February 17, 2022
mRNA vaccine-induced antibodies more effective than natural immunity in neutralizing SARS-CoV-2 and its high affinity variantsYunkai Yu, Dominic Esposito, Zhigang Kang, et al.
Acta Oncologica (Stockholm, Sweden)|May 15, 2015
Late urinary toxicity modeling after stereotactic body radiotherapy (SBRT) in the definitive treatment of localized prostate cancerThomas P Kole, Michael Tong, Binbin Wu, et al.
Frontiers in Oncology|August 5, 2016
Proctitis 1 Week after Stereotactic Body Radiation Therapy for Prostate Cancer: Implications for Clinical Trial DesignIma Paydar, Robyn A Cyr, Thomas M Yung, et al.
Frontiers in Oncology|July 21, 2015
Dysuria Following Stereotactic Body Radiation Therapy for Prostate CancerEinsley-Marie Janowski, Thomas P Kole, Leonard N Chen, et al.
Frontiers in Oncology|December 19, 2013
Rationale for stereotactic body radiation therapy in treating patients with oligometastatic hormone-naïve prostate cancerOnita Bhattasali, Leonard N Chen, Michael Tong, et al.
Radiation Oncology (London, England)|April 19, 2015
Hematuria following stereotactic body radiation therapy (SBRT) for clinically localized prostate cancerMarie K Gurka, Leonard N Chen, Aditi Bhagat, et al.
Frontiers in Oncology|November 7, 2014
Improved irritative voiding symptoms 3 years after stereotactic body radiation therapy for prostate cancerZaker Rana, Robyn A Cyr, Leonard N Chen, et al.
Frontiers in Oncology|June 1, 2016
Acute Urinary Morbidity Following Stereotactic Body Radiation Therapy for Prostate Cancer with Prophylactic Alpha-Adrenergic Antagonist and Urethral Dose ReductionMichael C Repka, Shan Guleria, Robyn A Cyr, et al.
The Journal of Infectious Diseases|June 5, 2021
Naturally Acquired SARS-CoV-2 Immunity Persists for Up to 11 Months Following InfectionValeria De Giorgi, Kamille A West, Amanda N Henning, et al.
Radiation Oncology (London, England)|February 12, 2014
Patient-reported outcomes following stereotactic body radiation therapy for clinically localized prostate cancerOnita Bhattasali, Leonard N Chen, Jennifer Woo, et al.
Pageof 4